Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

Bibliography

• Freynhagen R, Baron R, Gockel U, Tolle TR. Paindetect: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20
   PubMed Web of Science ®Google Scholar
• Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from US national surveys, 2002. Spine 2006;31:2724-7
   PubMed Web of Science ®Google Scholar
• Hale ME, Fleischmann R, Salzman R, Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999;15:179-83
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21-8
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Katz N, Rauck R, Ahdieh H, A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23:117-28
   PubMed Web of Science ®Google Scholar
• Rauck RL, Bookbinder SA, Bunker TR, A randomized, open-label, multicenter trial comparing once-a-day avinza (morphine sulfate extended-release capsules) versus twice-a-day oxycontin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the action trial. J Opioid Manag 2007;3:35-43
   PubMedGoogle Scholar
• Rauck RL, Bookbinder SA, Bunker TR, The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA®) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin®) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2006;2:155-66
   PubMedGoogle Scholar
• Roth SH, Fleischmann RM, Burch FX, Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60
   PubMed Web of Science ®Google Scholar
• Chou R, Fanciullo GJ, Fine PG, Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
   PubMed Web of Science ®Google Scholar
• Bartleson JD. Evidence for and against the use of opioid analgesics for chronic nonmalignant low back pain: a review. Pain Med 2002;3:260-71
   PubMed Web of Science ®Google Scholar
• Schofferman J, Mazanec D. Evidence-informed management of chronic low back pain with opioid analgesics. Spine J 2008;8:185-94
   PubMed Web of Science ®Google Scholar
• Chou R, Ballantyne JC, Fanciullo GJ, Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147-59
   PubMed Web of Science ®Google Scholar
• Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North America 2003;21:699-713
   PubMedGoogle Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:r1046-51
   PubMed Web of Science ®Google Scholar
• Caldwell JR, Hale ME, Boyd RE, Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9
   PubMed Web of Science ®Google Scholar
• Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63:17-32
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, Opioid complications and side effects. Pain Physician 2008;11:s105-20
   PubMed Web of Science ®Google Scholar
• Bell TJ, Panchal SJ, Miaskowski C, The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 2009;10:35-42
   PubMed Web of Science ®Google Scholar
• Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61:1181-7
   PubMed Web of Science ®Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11s-8s
   PubMed Web of Science ®Google Scholar
• Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep 2001;5:237-40
   PubMedGoogle Scholar
• Tzschentke TM, Christoph T, Kogel B, (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ−opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, de Vry J, Terlinden R, Tapentadol HCl. Drugs Future 2006;31:1053-61
   Web of Science ®Google Scholar
• Hartrick C, Van hove I, Stegmann J-U, Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260-71
   PubMed Web of Science ®Google Scholar
• Stegmann J-U, Weber H, Steup A, The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008;24:3185-96
   PubMed Web of Science ®Google Scholar
• Daniels SE, Upmalis D, Okamoto A, A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765-76
   PubMed Web of Science ®Google Scholar
• Daniels S, Casson E, Stegmann J-U, A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009;25:1551-61
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. Available from: http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm129515.pdf [Last accessed 4 May 2010]
   Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 1994;23:129-38
   PubMedGoogle Scholar
• Ware JE Jr, Donald Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
   PubMed Web of Science ®Google Scholar
• Haythornthwaite JA, Hegel MT, Kerns RD. Development of a sleep diary for chronic pain patients. J Pain Symptom Manage 1991;6:65-72
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003;35:253-9
   PubMed Web of Science ®Google Scholar
• Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006;10:209-17
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, Lamoreaux L, Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;6:357-66
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010; In press
   Google Scholar
• Afilalo M, Kuperwasser B, Kelly K, Efficacy and safety of tapentadol extended release (ER) for chronic pain due to osteoarthritis of the knee: results of a phase 3 study. Pain Pract 2009;9:159
   Google Scholar
• Etropolski M, Shapiro DY, Okamoto A, Efficacy and safety of tapentadol ER for diabetic peripheral neuropathic pain: results of a randomized-withdrawal, double-blind, placebo-controlled phase III study. Neurology 2009;72(Suppl 3):A217-8
   Google Scholar
• Hale M, Upmalis D, Okamoto A, Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009;25:1095-104
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Jahnel U, Kogel B, Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 2009;45:483-96
   PubMed Web of Science ®Google Scholar
• Terlinden R, Kogel B, Englberger W, Tzschentke T. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8
   Google Scholar
• Minami K, Uezono Y, Ueta Y. Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci 2007;103:253-60
   PubMed Web of Science ®Google Scholar
• Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988;38:877-80
   PubMed Web of Science ®Google Scholar
• Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996;15:8-29
   PubMed Web of Science ®Google Scholar
• Dalton JA, Youngblood R. Clinical application of the World Health Organization analgesic ladder. J Intraven Nurs 2000;23:118-24
   PubMedGoogle Scholar
• Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc) 2008;44:827-36
   PubMed Web of Science ®Google Scholar
• Babul N, Noveck R, Chipman H, Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004;28:59-71
   PubMed Web of Science ®Google Scholar
• Pascual ML, Fleming RR, Gana TJ, Vorsanger GJ. Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain. Curr Med Res Opin 2007;23:2531-42
   PubMed Web of Science ®Google Scholar
• Vorsanger GJ, Xiang J, Gana TJ, Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008;4:87-97
   PubMedGoogle Scholar
• Kelly K, Kuperwasser B, Okamoto A, Efficacy and gastrointestinal tolerability of tapentadol extended release in a randomized, double-blind, placebo- and active-controlled study in patients with moderate-to-severe chronic osteoarthritis knee pain. Pain Pract 2009;9:161-2
   Google Scholar
• Etropolski MS, Shapiro DY, Okamoto A, Safety and tolerability of tapentadol extended release in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal phase 3 study. Diabetes 2009;58:a226-7
   Web of Science ®Google Scholar
• Barann M, Urban B, Stamer U, Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol 2006;531:54-8
   PubMed Web of Science ®Google Scholar
• Arnold R. Why patients do not take their opioids. J Palliat Med 2004;7:716-7
   PubMedGoogle Scholar
• Bhamb B, Brown D, Hariharan J, Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006;22:1859-65
   PubMed Web of Science ®Google Scholar
• Gureje O, Von KM, Simon GE, Gater R. Persistent pain and well-being: a world health organization study in primary care. JAMA 1998;280:147-51
   PubMed Web of Science ®Google Scholar
• Becker N, Bondegaard TA, Olsen AK, Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997;73:393-400
   PubMed Web of Science ®Google Scholar
• Ashburn MA, Staats PS. Management of chronic pain. Lancet 1999;353:1865-9
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Peirce-Sandner S, Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010;149:177-93
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13:185-90
   PubMed Web of Science ®Google Scholar
• Schmidt CO, Schweikert B, Wenig CM, Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain 2009;13:1030-5
   Google Scholar
• Davis MP. What is new in neuropathic pain? Support Care Cancer 2007;15:363-72
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar